 Starting at Week 12, subjects who experience a disease flare flare is defined by an increase in the Harvey Bradshaw Index 3 and a total Index score of 7 when compared to Week 4 or are not responding to adalimumab treatment non-response is defined as a decrease in the Harvey Bradshaw Index by fewer than 3 points compared to Baseline will be permitted to increase study therapy to adalimumab 40 mg every week. 